Olaparib treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status: Phase II LIGHT study primary analysis

Olaparib treatment resulted in significant improvement in objective response rates (ORRs) and progression-free survival (PFS) over non‑platinum chemotherapy in patients with BRCA1/BRCA2-mutated (BRCAm) platinum-sensitive relapsed ovarian cancer (PSROC) and ≥2 prior lines of platinum-based chemothera...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Gynecologic oncology 2022-09, Vol.166 (3), p.425-431
Hauptverfasser:	Cadoo, Karen, Simpkins, Fiona, Mathews, Cara, Liu, Ying L., Provencher, Diane, McCormick, Colleen, ElNaggar, Adam C., Altman, Alon D., Gilbert, Lucy, Black, Destin, Kabil, Nashwa, Bennett, James, Munley, Jiefen, Aghajanian, Carol
Format:	Artikel
Sprache:	eng
Schlagworte:	BRCA BRCA1 Protein - genetics BRCA2 Protein - genetics Carcinoma, Ovarian Epithelial - drug therapy Carcinoma, Ovarian Epithelial - genetics Female Homologous Recombination Homologous recombination deficiency Humans Mutation Neoplasm Recurrence, Local - drug therapy Neoplasm Recurrence, Local - genetics Olaparib Ovarian cancer Ovarian Neoplasms - drug therapy Ovarian Neoplasms - genetics Ovarian Neoplasms - pathology Phthalazines Piperazines Treatment
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!